Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations

This publication has 28 references indexed in Scilit:

• Extended-spectrum ?-lactamases: A challenge for clinical microbiologists and infection control specialists
  American Journal of Infection Control, 2005
• The New β-Lactamases
  New England Journal of Medicine, 2005
• Bloodstream Infections Due to Extended-Spectrum β - Lactamase-Producing Escherichia coli and Klebsiella pneumoniae : Risk Factors for Mortality and Treatment Outcome, with Special Emphasis on Antimicrobial Therapy
  Antimicrobial Agents and Chemotherapy, 2004
• The Commonality of Risk Factors for Nosocomial Colonization and Infection with Antimicrobial-Resistant Staphylococcus aureus, Enterococcus, Gram-Negative Bacilli, Clostridium difficile, and Candida
  Annals of Internal Medicine, 2002
• Molecular Correlation for the Treatment Outcomes in Bloodstream Infections Caused byEscherichia coliandKlebsiella pneumoniaewith Reduced Susceptibility to Ceftazidime
  Clinical Infectious Diseases, 2002
• Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat
  Clinical Microbiology Reviews, 2001
• Outcome of Cephalosporin Treatment for Serious Infections Due to Apparently Susceptible Organisms Producing Extended-Spectrum β-Lactamases: Implications for the Clinical Microbiology Laboratory
  Journal of Clinical Microbiology, 2001
• National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, Issued June 1999
  American Journal of Infection Control, 1999
• Surveillance of Antimicrobial Use and Antimicrobial Resistance in United States Hospitals: Project ICARE Phase 2
  Clinical Infectious Diseases, 1999
• State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
  Clinical Infectious Diseases, 1998